搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
3 天
Incyte股票因专利悬崖担忧被下调评级
周三,Truist Securities调整了对Incyte Corporation (NASDAQ:INCY)的立场,将该股票从买入下调至持有,同时将目标价从83美元下调至74美元。这一决定是因为这家生物制药公司即将面临其旗舰产品Jakafi的专利到期。 在最近的一份声明中,Truist Securities承认Incyte成功推出了Opzelura并努力使其管线多样化。尽管如此,该公司表示担心 ...
AOL
3 天
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...
FiercePharma
7 天
ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...
5 天
Incyte维持TD Cowen买入评级,ESMO数据后评估不变
生物制药公司Incyte Corporation (NASDAQ: INCY)在TD Cowen的评级中保持买入评级,目标价为80.00美元。 这一评估是在公司在欧洲肿瘤内科学会(ESMO)会议上展示更新数据之后做出的。 新数据来自其CDK2抑制剂'667的I期研究,该药物正在晚期实体瘤患者中进行测试。 更新的结果显示,随着更长的随访期和更高的剂量,'667导致的反应数量比早期结果增加。具体而言, ...
3 天
Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary ...
Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo(axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...
Zacks.com on MSN
5 天
Incyte Announces Promising New Data on Oncology Candidate at ESMO
Incyte INCY announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid ...
3 天
Incyte Corp. stock underperforms Wednesday when compared to competitors
Shares of Incyte Corp. INCY slid 1.90% to $65.17 Wednesday, on what proved to be an all-around grim trading session for the ...
5 天
Incyte’s Promising Clinical Trials Underpin Buy Rating
Incyte (INCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebovitz from ...
pharmaphorum
6 天
ESMO: Incyte's PD-1 treads new ground in anal cancer
Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...
STAT
5 天
Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial
A common immunotherapy approach helped stave off disease progression in patients with a form of anal cancer that is caused by ...
7 天
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in ...
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, ...
5 天
Incyte’s Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics
JMP Securities analyst Reni Benjamin has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Reni Benjamin has ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈